{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:21:04Z","timestamp":1783650064973,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.rmed.2018.03.019","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T21:09:06Z","timestamp":1521234546000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study \u2013 Rationale and study design"],"prefix":"10.1016","volume":"138","author":[{"given":"J\u00fcrgen","family":"Behr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Uwe","family":"Kirchgaessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bengus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2018.03.019_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1378\/chest.10-2572","article-title":"Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium","volume":"140","author":"Nathan","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib3","first-page":"5","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.rmed.2018.03.019_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1378\/chest.127.1.284","article-title":"Health-related quality of life among patients with idiopathic pulmonary fibrosis","volume":"127","author":"Swigris","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1183\/09031936.01.17509540","article-title":"Quality of life of idiopathic pulmonary fibrosis patients","volume":"17","author":"De Vries","year":"2001","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib6","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib8","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1183\/09031936.00131813","article-title":"6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis","volume":"43","author":"du Bois","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200308-1142OC","article-title":"Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension","volume":"170","author":"Leuchte","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib11","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"128","author":"Nadrous","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.06-1466","article-title":"Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis","volume":"131","author":"Hamada","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1378\/chest.07-0116","article-title":"High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis","volume":"132","author":"Zisman","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.00107206","article-title":"Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant","volume":"30","author":"Shorr","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.129.3.746","article-title":"Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis","volume":"129","author":"Lettieri","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib16","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1183\/13993003.00395-2016","article-title":"Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science","volume":"47","author":"Hassoun","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.rmed.2018.03.019_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib22","series-title":"Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias","first-page":"2017","author":"Bayer Corporation","year":"2016"},{"key":"10.1016\/j.rmed.2018.03.019_bib23","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib24","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2018.03.019_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc053442","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"354","author":"Hoeper","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.rmed.2018.03.019_bib27","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.113.005698","article-title":"STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension","volume":"129","author":"Barst","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.rmed.2018.03.019_bib28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2012.082065","article-title":"Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.rmed.2018.03.019_bib29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2018.03.019_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","article-title":"Sildenafil improves walk distance in idiopathic pulmonary fibrosis","volume":"131","author":"Collard","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00408-009-9209-8","article-title":"Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis","volume":"188","author":"Jackson","year":"2010","journal-title":"Lung"},{"key":"10.1016\/j.rmed.2018.03.019_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib33","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib34","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1378\/chest.12-1330","article-title":"Out-of-proportion pulmonary hypertension: a paradigm for rare diseases","volume":"142","author":"Harari","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.03.019_bib35","first-page":"A1432","article-title":"The use of pirfenidone in combination with sildenafil for advanced idiopathic pulmonary fibrosis [abstract]","volume":"189","author":"Riddell","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib36","series-title":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","first-page":"2017","author":"National Institutes of Health","year":"2010"},{"key":"10.1016\/j.rmed.2018.03.019_bib37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/jamacardio.2017.3882","article-title":"Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension","volume":"2","author":"Assad","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.rmed.2018.03.019_bib39","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.rmed.2018.03.019_bib40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000345221","article-title":"Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis","volume":"85","author":"Kimura","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2018.03.019_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/thx.2008.112847","article-title":"Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension","volume":"64","author":"Corte","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.03.019_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry","volume":"46","author":"Behr","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib43","first-page":"A2698","article-title":"PROOF: A prospective observational registry to describe the disease course and outcomes of early idiopathic pulmonary fibrosis patients in a real-world clinical setting. PROOF-Registry Belgium - Luxembourg: comorbidities in 175 patients at inclusion","volume":"193","author":"Wuyts","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib44","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC)","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1755-5922.12084","article-title":"Outcome of patients with severe PH due to lung disease with and without targeted therapy","volume":"32","author":"Lange","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.rmed.2018.03.019_bib47","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib48","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1183\/13993003.01259-2015","article-title":"Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo\/in vitro study","volume":"47","author":"Milara","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.03.019_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2016.04.010","article-title":"Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial","volume":"36","author":"Vitulo","year":"2017","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.rmed.2018.03.019_bib50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rmed.2014.01.003","article-title":"Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review","volume":"108","author":"Wang","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2018.03.019_bib51","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.rmed.2018.03.019_bib52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","article-title":"Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults","volume":"22","author":"Rubino","year":"2009","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2018.03.019_bib53","first-page":"13S","article-title":"Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil","volume":"53","author":"Muirhead","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2018.03.019_bib54","first-page":"5S","article-title":"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality","volume":"53","author":"Nichols","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.rmed.2018.03.019_bib55","first-page":"297","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis does not influence six-minute walk distance: results from a retrospective study","volume":"31","author":"Harari","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.rmed.2018.03.019_bib56","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.126.1_suppl.7S","article-title":"Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"Rubin","year":"2004","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118300830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118300830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:39:33Z","timestamp":1760614773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118300830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":56,"alternative-id":["S0954611118300830"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.03.019","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study \u2013 Rationale and study design","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}